We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+14.46%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$257M
AUM Growth
-$6.27M
Cap. Flow
-$29.2M
Cap. Flow %
-11.36%
Top 10 Hldgs %
53.62%
Holding
74
New
14
Increased
16
Reduced
17
Closed
18

Top Buys

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$3.75M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.53M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$3.48M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$3.35M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.35M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.04M
2
VTRS icon
Viatris
VTRS
+$5.43M
3
SHPG
Shire pic
SHPG
+$5.4M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$5.01M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
26
DELISTED
Array Biopharma Inc
ARRY
$3.04M 1.18%
247,500
-73,244
-23% -$680K
CALA
27
DELISTED
Calithera Biosciences, Inc
CALA
$2.95M 1.15%
9,400
-2,800
-23% -$883K
DERM
28
DELISTED
Dermira, Inc.
DERM
$2.92M 1.14%
108,000
-21,000
-16% -$550K
JUNO
29
DELISTED
Juno Therapeutics, Inc.
JUNO
$2.82M 1.1%
+63,000
New +$2.15M
SGYP
30
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$2.8M 1.09%
971,922
+199,922
+26% +$682K
BLUE
31
DELISTED
bluebird bio
BLUE
$2.75M 1.07%
+1,544
New +$2.16M
IONS icon
32
Ionis Pharmaceuticals
IONS
$10.4B
$2.61M 1.02%
51,500
– –
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$2.15M 0.84%
322,436
– –
STML
34
DELISTED
Stemline Therapeutics, Inc.
STML
$2.03M 0.79%
182,930
-270,070
-60% -$2.54M
KYNB
35
Kyntra Bio
KYNB
$32.4M
$1.69M 0.66%
+1,256
New +$1.32M
AVXS
36
DELISTED
AveXis, Inc. Common Stock
AVXS
$1.64M 0.64%
+17,000
New +$1.53M
CORT icon
37
Corcept Therapeutics
CORT
$12.6B
$1.6M 0.62%
+83,000
New +$1.24M
VCYT icon
38
Veracyte
VCYT
$3.64B
$1.49M 0.58%
170,000
– –
AGIO icon
39
Agios Pharmaceuticals
AGIO
$2.05B
$1.33M 0.52%
20,000
-17,000
-46% -$1.02M
OMER icon
40
Omeros
OMER
$1.39B
$1.32M 0.51%
61,000
+30,761
+102% +$652K
PTLA
41
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.3M 0.5%
24,000
-52,000
-68% -$3.05M
ASXC
42
DELISTED
Asensus Surgical, Inc.
ASXC
$1.27M 0.49%
68,391
– –
AKAO
43
DELISTED
Achaogen Inc
AKAO
$1.19M 0.46%
74,538
-80,000
-52% -$1.52M
ONCE
44
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.07M 0.42%
+12,000
New +$911K
SAGE
45
DELISTED
Sage Therapeutics
SAGE
$1.06M 0.41%
16,996
– –
GTHX
46
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$971K 0.38%
+39,000
New +$720K
IRWD icon
47
Ironwood Pharmaceuticals
IRWD
$701M
$930K 0.36%
70,446
– –
FOLD
48
DELISTED
Amicus Therapeutics
FOLD
$883K 0.34%
+58,600
New +$775K
HZNP
49
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$876K 0.34%
69,000
-100,000
-59% -$1.27M
SUPN icon
50
Supernus Pharmaceuticals
SUPN
$2.57B
$838K 0.33%
20,953
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2017 Portfolio in Review

As of Q3 2017, International Biotechnology Trust held 74 positions worth $257M, down 2.4% from $263M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

International Biotechnology Trust withdrew a net $29.2M in Q3 2017, closing 18 positions and reducing 17 holdings. Its most notable exit was Viatris, an estimated $5.43M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Alnylam Pharmaceuticals worth $4.85M.

  • International Biotechnology Trust's largest Q3 2017 buy was Alnylam Pharmaceuticals: 41,300 shares worth $4.85M.
  • International Biotechnology Trust added most to Adamas Pharmaceuticals in Q3 2017, an estimated $3.75M increase.
  • International Biotechnology Trust's biggest Q3 2017 reduction was Vertex Pharmaceuticals, cutting an estimated $7.04M.
  • International Biotechnology Trust fully exited Viatris in Q3 2017, selling an estimated $5.43M.
  • International Biotechnology Trust's ten largest holdings make up 54% of its $257M portfolio in Q3 2017.
  • International Biotechnology Trust opened 14 new positions and closed 18 in Q3 2017.
  • International Biotechnology Trust's portfolio value fell 2.4% quarter-over-quarter to $257M.

Based on International Biotechnology Trust's 13F filing for Q3 2017, filed 2 Mar 2018.